We are excited to share that CONQUEST, a global platform clinical trial created by the Scleroderma Research Foundation, has opened 68 sites in 13 countries. Individuals with interstitial lung disease associated with systemic sclerosis (SSc-ILD) who qualify for the trial can now enroll in sites across the world, including in the United States, Japan, several European countries, and others.
Launched in April 2024, CONQUEST was developed with input from partner biopharmaceutical companies to accelerate the development of scleroderma treatment options. With its global network of scleroderma treatment centers, CONQUEST aims to make a widespread impact on scleroderma research, with plans to enroll 430 patients in its first iteration.
